INS and metabolic dysfunction-associated steatohepatitis: LC with 2000 mg daily for 24 weeks resulted in lower glucose and plasma lipid levels in NASH patients [31] as well as improved insulin sensitivity [32], whereas 19 months treatment with a very low dose of 100 mg/kg LC daily in mice did not reveal any significant effects on plasma lipid levels [33].